Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution M. V. Uthaug, K. van Oorsouw, K. P. C. Kuypers, M. van Boxtel, N. J. Broers, N. L. Mason, S. W. Toennes, J. Riba, J. G. Ramaekers Psychopharmacology, 2018 https://doi.org/10.1007/s00213-018-4988-3 Abstract Rationale : Ayahuasca is a psychotropic plant tea from South America used for religious purposes by indigenous people of the Amazon. Increasing evidence indicates that ayahuasca may have therapeutic potential in the treatment of mental health disorders and can enhance mindfulness-related capacities. Most research so far has focused on acute and sub-acute effects of ayahuasca on [...]
Lire la suiteAyahuasca and Public Health : Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users Genís Ona, Maja Kohek, Tomàs Massaguer, Alfred Gomariz, Daniel F. Jiménez, Rafael G. Dos Santos, Jaime E. C. Hallak, Miguel Ángel Alcázar- Córcoles & José Carlos Bouso Journal of Psychoactive Drugs, 2019, DOI: 10.1080/02791072.2019.1567961 ABSTRACT Assessing the health status of ayahuasca users has been challenging due to the limitations involved in randomized clinical trials and psychometric approaches. The main objective of this study is the implementation of an approach based on public health indicators. We developed a self-administered questionnaire that was administered to long-term [...]
Lire la suiteHarm potential of magic mushroom use : A review Jan van AMSTERDAM, Antoon OPPERTHUIZEN, Wim van den BRINK Regulatory Toxicology and Pharmacology, 2011, 59, 423-429. Doi : 10.1016/j.yrtph.2011.01.006 Abstract In 2007, the Minister of Health of the Netherlands requested the CAM (Coordination point Assessment and Monitoring new drugs) to assess the overall risk of magic mushrooms. The present paper is an updated redraft of the review, written to support the assessment by CAM experts. It summarizes the literature on physical or psychological dependence, acute and chronic toxicity, risk for public health and criminal aspects related to the consumption of magic mushrooms. In the Netherlands, the [...]
Lire la suiteProhibited or regulated ? LSD psychotherapy and the United States Food and Drug Administration Matthew Oram History of Psychiatry, 2016, 27, (3), 290-306. Doi : 10.1177/0957154X16648822 Abstract Over the 1950s and early 1960s, the use of the hallucinogenic drug lysergic acid diethylamide (LSD) to facilitate psychotherapy was a promising field of psychiatric research in the USA. However, during the 1960s, research began to decline, before coming to a complete halt in the mid-1970s. This has commonly been explained through the increase in prohibitive federal regulations during the 1960s that aimed to curb the growing recreational use of the drug. However, closely examining the Food and Drug [...]
Lire la suiteFlashback : Psychiatric Experimentation With LSD in Historical Perspective Erika Dyck Canadian Journal of Psychiatry, 2005, Vol 50, No 7, 381-388. Doi : 10.1177/070674370505000703 In the popular mind, d-lysergic acid diethylamide (LSD) research in psychiatry has long been associated with the CIA-funded experiments conducted by Ewen Cameron at the Allen Memorial Institute in Montreal, Quebec. Despite this reputation, a host of medical researchers in the post–World War II era explored LSD for its potential therapeutic value. Some of the most widespread trials in the Western world occurred in Saskatchewan, under the direction of psychiatrists Humphry Osmond (in Weyburn) and Abram Hoffer (in Saskatoon). These [...]
Lire la suitePsychedelic microdosing benefits and challenges : an empirical codebook Thomas Anderson, Rotem Petranker, Adam Christopher, Daniel Rosenbaum, Cory Weissman, Le-Anh Dinh-Williams, Katrina Hui, Emma Hapke Harm Reduction Journal, 2019. Doi : 10.1186/s12954-019-0308-4 Abstract Background : Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. Methods : In the present study, [...]
Lire la suiteToujours plus avec la chimie psychédélique par Thibault Henneton Manière de Voir (Le Monde Diplomatique), 2019, 163, Fruits d’une inventivité chimique sans limites, les nouveaux produits de synthèse (NPS) se sont multipliés ces dix dernières années, notamment dans les milieux festifs alternatifs. Moins chers que la cocaïne, ils restent difficiles à cerner tant pour les autorités que pour les usagers, incapables d’en connaître à l’avance les effets véritables, dont certains mènent aux hôpitaux, désarmés pour les traiter. Akatre ///// « Djeff », 2018 Placés récemment sous les projecteurs, les nouveaux produits de synthèse (NPS) inonderaient le marché des stupéfiants. Dans son dernier rapport annuel, l’Observatoire français des [...]
Lire la suiteLSD before Leary - Sidney Cohen' s Critique of 1950s Psychedelic Drug Research Steven J. Novak Isis, 1997, Vol. 88, No. 1, pp. 87-110. http://links.jstor.org/sici?sici=0021-1753%28199703%2988%3A1%3C87%3ALBLSCC%3E2.0.CO%3B2-W ABSTRACT In 1962 Sidney Cohen presented the medical community with its first warning about the dangers of the drug LSD. LSD had arrived in the United States in 1949 and was originally perceived as a psychoto-mimetic capable of producing a model psychosis. But in the mid 1950s intellectuals in Southern California redefined LSD as a psychedelic capable of producing mystical enlightenment. Though LSD was an investigational drug, authorized only for experimental use, by the late 1950s psychiatrists and psychologists were [...]
Lire la suitehttp://psychedelic-library.org/lsdmenu.htm Alas! the forbidden fruits were eaten, And thereby the warm life of reason congealed. A grain of wheat eclipsed the sun of Adam, Like as the Dragon's tail dulls the brightness of the moon. — Rumi: Masnavi I Ma'navi Introductory Papers The Exploration of Experience by: Humphrey Osmond, an excerpt from his 1957 paper "A Review of the Clinical Effects of Psychotomimetic Agents" Psychedelics, Technology, Psychedelics by: Bernard Aaronson and Humphry Osmond, the introductory chapter to PSYCHEDELICS, the Uses and Implications of Hallucinogenic Drugs Psychedelics and the Future by Humphry Osmond and Bernard S. Aaronson Request for a Public Hearing to: The Hearing Clerk, Department of Health, Education and Welfare Menus Psychotherapy and Psychedelic Drugs Psychedelic Research [...]
Lire la suitePharmacology of Consciousness or Pharmacology of Spirituality ? A Historical Review of Psychedelic Clinical Studies Ismael Apud The Journal of Transpersonal Psychology, 2016, Vol. 48, No. 2, 150-167. ABSTRACT: In the second half of the twentieth century, when psychopharmacology was not developed as we know it today and psychoanalysis was an influential school, various psychiatrists began to develop a ‘pharmacology of consciousness,’ and became interested in hallucinogens as new paths for accessing the unconscious. However, with the psychedelic model, the pharmacology of consciousness turned also into a ‘pharmacology of spirituality,’ focused on the use of spiritual experiences as catalyzers of psychological change. This article [...]
Lire la suite